Aaron Freidin Sells 2,492 Shares of GRAIL (NASDAQ:GRAL) Stock

GRAIL, Inc. (NASDAQ:GRAL) CFO Aaron Freidin sold 2,492 shares of GRAIL stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $47.89, for a total transaction of $119,341.88. Following the completion of the transaction, the chief financial officer owned 306,475 shares of the company’s stock, valued at $14,677,087.75. This represents a 0.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Aaron Freidin also recently made the following trade(s):

• On Thursday, March 5th, Aaron Freidin sold 655 shares of GRAIL stock. The stock was sold at an average price of $53.01, for a total value of $34,721.55.
• On Monday, March 2nd, Aaron Freidin sold 9,573 shares of GRAIL stock. The stock was sold at an average price of $50.17, for a total value of $480,277.41.

GRAIL Price Performance

GRAIL stock opened at $48.67 on Wednesday. The firm has a market capitalization of $1.90 billion, a P/E ratio of -4.35 and a beta of 5.18. GRAIL, Inc. has a one year low of $20.44 and a one year high of $118.84. The business has a fifty day moving average price of $87.41 and a 200-day moving average price of $78.10.

GRAIL (NASDAQ:GRAL) last released its quarterly earnings data on Thursday, February 19th. The company reported ($2.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.33) by $0.89. The company had revenue of $43.60 million for the quarter, compared to analyst estimates of $43.33 million. GRAIL had a negative return on equity of 17.58% and a negative net margin of 277.46%. Sell-side analysts expect that GRAIL, Inc. will post -15.15 earnings per share for the current fiscal year.

Institutional Trading of GRAIL

Institutional investors and hedge funds have recently modified their holdings of the business. WIM INVESTMENT MANAGEMENT Ltd grew its position in GRAIL by 200.0% in the third quarter. WIM INVESTMENT MANAGEMENT Ltd now owns 63,000 shares of the company’s stock worth $3,725,000 after acquiring an additional 42,000 shares in the last quarter. JPMorgan Chase & Co. raised its position in GRAIL by 159.1% during the third quarter. JPMorgan Chase & Co. now owns 206,120 shares of the company’s stock valued at $12,188,000 after purchasing an additional 126,576 shares in the last quarter. Caxton Associates LLP bought a new stake in GRAIL during the second quarter worth about $3,320,000. NWF Advisory Services Inc. bought a new stake in GRAIL during the second quarter worth about $1,062,000. Finally, Y Intercept Hong Kong Ltd purchased a new position in shares of GRAIL in the 3rd quarter worth about $885,000.

Key GRAIL News

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: Institutions adding stakes: Several large funds materially increased positions in Q4 (Farallon, Morgan Stanley, State Street, Baker Bros.), signaling confidence from sophisticated investors and providing a steady demand base. MarketBeat institutional ownership summary
• Positive Sentiment: Recent quarterly results beat EPS estimates (reported ($2.44) vs consensus ($3.33)) and revenue was roughly in line, which supports the case that core business traction (Galleri test adoption) is progressing. (Market reaction is mixed given continued multi-year losses.) Earnings & analyst summary
• Neutral Sentiment: Mixed analyst activity: Some firms trimmed price targets (Morgan Stanley cut to $60, Canaccord lowered targets), while others remain bullish (Guggenheim raised its target earlier). Overall consensus remains around a “Hold” with divergent price targets, adding to uncertainty on near-term direction. Analyst notes
• Negative Sentiment: Short interest jumped in February to ~6.3M shares (16.2% of float), up ~15% from mid‑February; days-to-cover ~1.9. A higher short percent increases downward pressure and volatility, especially given GRAL’s high beta. (Elevated shorting can amplify declines while also enabling short‑squeeze risk.)
• Negative Sentiment: Insider selling by top executives: CEO Robert Ragusa, President Joshua Ofman and CFO Aaron Freidin reported multiple sales in early March (CEO sale filings: Read More.; President filings: Read More.; CFO filings: Read More.). While sizes are modest vs. their holdings, clustered executive sales can spook investors and weigh on sentiment. InsiderTrades article

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on GRAL shares. Weiss Ratings reissued a “sell (d-)” rating on shares of GRAIL in a report on Thursday, January 22nd. TD Cowen assumed coverage on shares of GRAIL in a research note on Thursday, February 19th. They set a “hold” rating and a $114.00 price objective for the company. Guggenheim upped their target price on shares of GRAIL from $100.00 to $130.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Robert W. Baird set a $82.00 target price on shares of GRAIL in a research note on Friday, February 20th. Finally, Morgan Stanley cut their price target on shares of GRAIL from $110.00 to $60.00 and set an “equal weight” rating for the company in a report on Tuesday, February 24th. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $90.17.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.